{"presentation":{"slides":[{"elements":[{"x":5.446623093681917,"y":17.204301075268816,"width":89.54248366013073,"height":79.56989247311827,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","file":{"path":"images\/file-648965e91b6d5.jpg","mime":"image\/jpeg","copyright":{"license":"U"},"width":1207,"height":544},"alt":"Shorter - pre treat","expandImage":"Expand Image","minimizeImage":"Minimize Image"},"subContentId":"4cab4530-a1e3-4beb-ac4b-9377c8d9dbb1","metadata":{"contentType":"Image","license":"U","title":"Untitled Image"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":1.0893246187363834,"y":2.1451612903225805,"width":98.91067538126362,"height":15.053763440860214,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

The table below provides the details about the clinical evaluation and laboratory tests that need to be done during Pre-treatment Evaluation (PTE) to initiate patients on shorter injectable-containing Multidrug-resistant (MDR)\/ Rifampicin-resistant Tuberculosis (RR-TB) regimens.<\/span><\/p>\n\n

<\/p>\n"},"subContentId":"b198f530-6308-4898-8eff-87037bf24848","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":25.05446623093682,"y":21.50537634408602,"width":66.94560669456067,"height":33.149171270718234,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"

Audiometry: Baseline and then every 2 months till Second-Line Injectable (SLI) (Kanamycin (Km)\/ Amikacin (Am)) course is completed and then, as and when clinically indicated <\/li>\n\t
Serum creatinine: Baseline and then monthly till SLI course is completed.<\/li>\n<\/ul>\n\n
<\/p>\n"},"subContentId":"e4ade2ba-efc0-4996-9e80-10dd3e67d944","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":5.578800557880056,"y":16.574585635359117,"width":18.688981868898185,"height":38.67403314917127,"action":{"library":"H5P.Image 1.1","params":{"decorative":false,"contentName":"Image","file":{"path":"images\/file-64969f7837f5e.png","mime":"image\/png","copyright":{"license":"U"},"width":172,"height":180},"expandImage":"Expand Image","minimizeImage":"Minimize Image"},"subContentId":"8b5595dd-c480-4877-a64a-c16f3661b9cc","metadata":{"contentType":"Image","license":"U","title":"Untitled Image"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":5.578800557880056,"y":63.53591160220994,"width":90.6555090655509,"height":13.812154696132596,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"
The rest of the management would be the same as for shorter all oral Bedaquiline (Bdq) - containing MDR\/ RR-TB regimen.<\/p>\n"},"subContentId":"42e7d773-7d0b-4594-bf1d-cd01c40b6523","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""},{"x":37.65690376569038,"y":8.287292817679559,"width":40.0278940027894,"height":6.629834254143646,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"
Follow-up Investigations<\/strong><\/p>\n"},"subContentId":"afaf4f1b-b514-4905-a942-666536342482","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}},{"elements":[{"x":4.184100418410042,"y":11.049723756906078,"width":89.2608089260809,"height":40.05524861878453,"action":{"library":"H5P.AdvancedText 1.1","params":{"text":"
Resources<\/strong><\/p>\n\n
Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, March 2021<\/a>.<\/p>\n"},"subContentId":"e0961778-b4f8-4f1f-89a7-3ffe7329a67f","metadata":{"contentType":"Text","license":"U","title":"Untitled Text"}},"alwaysDisplayComments":false,"backgroundOpacity":0,"displayAsButton":false,"buttonSize":"big","goToSlideType":"specified","invisible":false,"solution":""}],"slideBackgroundSelector":{}}],"keywordListEnabled":true,"globalBackgroundSelector":{},"keywordListAlwaysShow":false,"keywordListAutoHide":false,"keywordListOpacity":90},"override":{"activeSurface":false,"hideSummarySlide":false,"summarySlideSolutionButton":true,"summarySlideRetryButton":true,"enablePrintButton":false,"social":{"showFacebookShare":false,"facebookShare":{"url":"@currentpageurl","quote":"I scored @score out of @maxScore on a task at @currentpageurl."},"showTwitterShare":false,"twitterShare":{"statement":"I scored @score out of @maxScore on a task at @currentpageurl.","url":"@currentpageurl","hashtags":"h5p, course"},"showGoogleShare":false,"googleShareUrl":"@currentpageurl"}},"l10n":{"slide":"Slide","score":"Score","yourScore":"Your Score","maxScore":"Max Score","total":"Total","totalScore":"Total Score","showSolutions":"Show solutions","retry":"Retry","exportAnswers":"Export text","hideKeywords":"Hide sidebar navigation menu","showKeywords":"Show sidebar navigation menu","fullscreen":"Fullscreen","exitFullscreen":"Exit fullscreen","prevSlide":"Previous slide","nextSlide":"Next slide","currentSlide":"Current slide","lastSlide":"Last slide","solutionModeTitle":"Exit solution mode","solutionModeText":"Solution Mode","summaryMultipleTaskText":"Multiple tasks","scoreMessage":"You achieved:","shareFacebook":"Share on Facebook","shareTwitter":"Share on Twitter","shareGoogle":"Share on Google+","summary":"Summary","solutionsButtonTitle":"Show comments","printTitle":"Print","printIngress":"How would you like to print this presentation?","printAllSlides":"Print all slides","printCurrentSlide":"Print current slide","noTitle":"No title","accessibilitySlideNavigationExplanation":"Use left and right arrow to change slide in that direction whenever canvas is selected.","accessibilityCanvasLabel":"Presentation canvas. Use left and right arrow to move between slides.","accessibilityProgressBarLabel":"Choose slide to display","containsNotCompleted":"@slideName contains not completed interaction","containsCompleted":"@slideName contains completed interaction","slideCount":"Slide @index of @total","containsOnlyCorrect":"@slideName only has correct answers","containsIncorrectAnswers":"@slideName has incorrect answers","shareResult":"Share Result","accessibilityTotalScore":"You got @score of @maxScore points in total","accessibilityEnteredFullscreen":"Entered fullscreen","accessibilityExitedFullscreen":"Exited fullscreen","confirmDialogHeader":"Submit your answers","confirmDialogText":"This will submit your results, do you want to continue?","confirmDialogConfirmText":"Submit and see results","slideshowNavigationLabel":"Slideshow navigation"}}

Search

Senior DR-TB/TB-HIV Supervisor: Shorter injectable containing regimen

Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up​

Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up